{"id":"https://openalex.org/W2590893558","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.4502","title":"Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC)","display_name":"Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC)","publication_year":2008,"publication_date":"2008-05-20","ids":{"openalex":"https://openalex.org/W2590893558","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.4502","mag":"2590893558"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2008.26.15_suppl.4502","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.4502","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.4502","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090156519","display_name":"Hedy Lee Kindler","orcid":"https://orcid.org/0000-0002-5450-842X","observed_orcids":["https://orcid.org/0000-0002-5450-842X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. L. Kindler","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109331981","display_name":"Tara C. Gangadhar","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. Gangadhar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038171309","display_name":"Theodore G Karrison","orcid":"https://orcid.org/0009-0009-8641-5111","observed_orcids":["https://orcid.org/0009-0009-8641-5111"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. Karrison","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112765038","display_name":"H. S. Hochster","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. S. Hochster","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003643368","display_name":"Malcolm J. Moore","orcid":"https://orcid.org/0009-0007-7493-3558","observed_orcids":["https://orcid.org/0009-0007-7493-3558"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. J. Moore","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048643621","display_name":"Kenneth C. Micetich","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Micetich","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"W. Sun","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. Sun","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084809433","display_name":"Daniel V.T. Catenacci","orcid":"https://orcid.org/0000-0001-7517-8020","observed_orcids":["https://orcid.org/0000-0001-7517-8020"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. V. Catenacci","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088131964","display_name":"Walter Michael Stadler","orcid":"https://orcid.org/0000-0002-0435-2527","observed_orcids":["https://orcid.org/0000-0002-0435-2527"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. M. Stadler","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5063904421","display_name":"Everett E. Vokes","orcid":"https://orcid.org/0000-0002-8645-8068","observed_orcids":["https://orcid.org/0000-0002-8645-8068"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. E. Vokes","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":34,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":"15_suppl","first_page":"4502","last_page":"4502"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10760","display_name":"Pancreatitis Pathology and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/advanced-pancreatic-cancer","display_name":"advanced pancreatic cancer","score":0.8309999704360962},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9800000190734863},{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":1.0},{"id":"https://openalex.org/keywords/egfr-inhibition","display_name":"EGFR inhibition","score":0.6140000224113464},{"id":"https://openalex.org/keywords/vegf-inhibition","display_name":"VEGF inhibition","score":0.9940000176429749},{"id":"https://openalex.org/keywords/dual-targeted-therapy","display_name":"dual-targeted therapy","score":0.8080000281333923},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.6759999990463257},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.4659999907016754},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.4970000088214874},{"id":"https://openalex.org/keywords/metastatic-pancreatic-cancer","display_name":"metastatic pancreatic cancer","score":0.6399999856948853},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.5440000295639038},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.5040000081062317}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9106017351150513},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7367569804191589},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.6893048286437988},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.6526810526847839},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.6406457424163818},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.5788288116455078},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.5608606338500977},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5170886516571045},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.4883536994457245},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.4642772078514099},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4451088309288025},{"id":"https://openalex.org/C2780210213","wikidata":"https://www.wikidata.org/wiki/Q212961","display_name":"Pancreatic cancer","level":3,"score":0.44454264640808105},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.34306570887565613},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.28481221199035645},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.24888363480567932},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.24366351962089539},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.223749041557312},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.11307346820831299}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2008.26.15_suppl.4502","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.4502","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.4502","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3010703934","https://openalex.org/W2248661719","https://openalex.org/W2243193473","https://openalex.org/W2094037194","https://openalex.org/W2061279654","https://openalex.org/W2026107878","https://openalex.org/W2124863710","https://openalex.org/W2278703263","https://openalex.org/W2340049292","https://openalex.org/W2591208317"],"abstract_inverted_index":{"4502":[0],"Background:":[1],"Targeting":[2],"several":[3],"critical":[4],"pathways":[5],"may":[6,294],"be":[7,295],"more":[8],"effective":[9],"than":[10],"single":[11],"pathway":[12],"blockade":[13],"in":[14,48,231,250,287],"a":[15,35],"resistant":[16],"cancer":[17],"like":[18],"PC.":[19],"In":[20],"preclinical":[21],"PC":[22,50,288],"models,":[23],"combining":[24],"EGFR":[25],"+":[26],"VEGF":[27],"targeted":[28,43],"agents":[29],"is":[30],"synergistic.":[31],"Methods:":[32],"We":[33],"conducted":[34],"multicenter,":[36],"randomized":[37,112],"phase":[38,284],"II":[39],"trial":[40],"of":[41,273],"dual":[42],"therapy,":[44],"GBC":[45,276],"or":[46,67,122,305,308],"GBE,":[47],"advanced":[49],"pts":[51,85,134,252],"who":[52],"had:":[53],"no":[54,64],"prior":[55],"therapy":[56],"for":[57,247],"metastatic":[58],"disease,":[59,63],"PS":[60,108,151],"0\u20132,":[61],"measurable":[62],"bleeding":[65],"risk":[66],"duodenal":[68],"invasion.":[69],"Primary":[70],"endpoint:":[71],"response;":[72],"2":[73,156,230,233,256],"parallel,":[74],"Simon":[75],"2-stage":[76],"designs.":[77],"Baseline":[78,218],"correlatives:":[79],"plasma":[80],"VEGF,":[81,219],"serum":[82],"VEGFR2.":[83],"All":[84],"received":[86],"G":[87,274],"1000":[88],"mg/m2":[89,116,120],"over":[90],"30\u2019":[91],"days":[92],"(D)":[93],"1,":[94,102],"8,":[95],"15":[96,103],"Q28D;":[97],"B":[98],"10":[99],"mg/kg":[100],"D":[101],"Q28D.":[104,130],"Pts,":[105],"stratified":[106],"by":[107,299],"and":[109,266,277,292],"site,":[110],"were":[111],"to":[113,270,282],"C":[114],"400":[115],"D1":[117],"then":[118],"250":[119],"Q7D,":[121],"E":[123],"150":[124],"mg":[125],"D1\u20135,":[126],"8-":[127],"12,":[128],"15\u201326":[129],"Results:":[131],"139":[132],"evaluable":[133],"(GBC/GBE":[135],"68/71)":[136],"enrolled":[137],"at":[138],"16":[139],"sites":[140],"9/04\u20132/07.":[141],"Pt":[142],"characteristics:":[143],"median":[144],"age":[145],"63/63":[146],"(range":[147],"36\u201383/39\u201386);":[148],"male":[149],"49%/70%;":[150],"0":[152],"35%/48%,":[153],"1":[154],"59%/46%,":[155],"6%/6%.":[157],"Cycles:":[158],"343/373":[159],"(median":[160],"4/4;":[161],"range":[162],"1\u201318/1\u201318).":[163],"Grade":[164],"3/4":[165],"toxicity":[166],"(%pts):":[167],"neutropenia":[168],"25%/31%;":[169],"thrombocytopenia":[170],"13%/21%;":[171],"thrombosis":[172],"16%/8%;":[173],"HTN":[174,228,291],"15%/11%;":[175],"rash":[176,254,293],"10%/6%;":[177],"diarrhea":[178],"3%/11%;":[179],"GI":[180],"bleed":[181],"3%/6%;":[182],"proteinuria":[183],"1%/6%.":[184],"Response:":[185],"complete":[186],"1%/3%,":[187],"partial":[188],"22%/15%,":[189],"stable":[190],"disease":[191],"49%/45%.":[192],"Median":[193,204],"overall":[194],"survival":[195,206],"(OS)":[196],"7.8/7.2":[197],"mo":[198,209],"(95%":[199,210],"CI:":[200,211],"5.3,":[201],"10.9/5.9,":[202],"10.5).":[203],"progression-free":[205],"(PFS)":[207],"5.0/5.1":[208],"3.6,":[212],"5.5/3.4,":[213],"5.9).":[214],"1-year":[215],"survival:":[216],"35%/30%.":[217],"VEGFR2":[220],"did":[221],"not":[222,242],"correlate":[223],"with":[224,236,253],"PFS,":[225,265],"OS.":[226,243],"Early":[227,290],"(\u2265grade":[229],"1st":[232],"cycles)":[234],"correlated":[235],"response":[237],"(44%":[238],"vs.":[239,258],"18%,":[240],"p=0.04),":[241],"There":[244],"was":[245],"trend":[246],"improved":[248],"OS":[249,267],"GBE":[251,278],"\u2265grade":[255],"(10.5":[257],"6.5":[259],"mo,":[260],"p=0.19).":[261],"Conclusion:":[262],"Although":[263],"RR,":[264],"are":[268],"superior":[269],"historical":[271],"controls":[272],"alone,":[275],"have":[279],"insufficient":[280],"activity":[281],"merit":[283],"III":[285],"evaluation":[286],"pts.":[289],"pharmacodynamic":[296],"markers.":[297],"Supported":[298],"NCI":[300],"N01-CM-17102":[301],"Author":[302],"Disclosure":[303],"Employment":[304],"Leadership":[306],"Consultant":[307],"Advisory":[309],"Role":[310],"Stock":[311],"Ownership":[312],"Honoraria":[313],"Research":[314],"Expert":[315],"Testimony":[316],"Other":[317],"Remuneration":[318],"Bristol-Myers":[319,326,333],"Squibb,":[320,327,334],"Genentech,":[321,328,335],"ImClone,":[322,329,336],"Lilly,":[323,330,337],"OSI,":[324,331],"Roche":[325,332],"OSI":[338,339]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2017-03-03T00:00:00"}